ReviewMolecular and clinical oncology2025
Retroperitoneal leiomyosarcoma with metastasis to the skin (Review).
Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroperitoneal leiomyosarcomas (RPLMS) are rare invasive malignant tumors originating from the smooth muscle of the retroperitoneum. Although metastasis mainly involves the lungs, liver and vascular regions, cutaneous metastasis is extremely rare, occurring in 1-2.6% of reported cases. This type of metastasis usually indicates disease progression, poor prognosis, median progression free survival of ~5 months, and overall survival of 14-17 months. Although recent molecular analyses have improved our understanding of the pathophysiology of leiomyosarcoma (LMS), the treatment of advanced LMS remains challenging, and there are few series of articles published primarily in case form. The present review explores the epidemiology, pathophysiology, clinical manifestations, diagnostic methods, and treatment strategies of skin metastasis in advanced RPLMS, in order to provide further reference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.